Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02320149 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
A Phase 3 study, sponsored by Almirall, S.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 968
- Enrollment target
NCT02320149: Completed Phase 3 study, sponsored by Almirall, S.A..
NCT02320149 is a Phase 3 study that has completed, run by Almirall, S.A.. The registered enrollment target is 968 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02320149, a Phase 3 study, has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 968 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris
Primary Outcome
Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 centimeter (cm) in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in
Interventions
- DRUG Placebo
- DRUG Sarecycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 968 participants |
| Start Date | 2014-12-18 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 3 |
What the finished NCT02320149 record still lists
NCT02320149 is an interventional study that assigns participants to a tested intervention. The registered 968 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (25% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02320149 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02320149 about?
NCT02320149 is a clinical study titled "Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne". To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris
What is the current status of trial NCT02320149?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 968 participants. The study started on 2014-12-18. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT02320149?
The interventions under investigation include: Placebo (DRUG), Sarecycline (DRUG).
Who is sponsoring clinical trial NCT02320149?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02320149's enrollment target sits among peer trials
968 330th of 2000 higher than 1,671 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05354141 · 970 participants · Phase 3
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI